Findings that a variant of the CIZ1 protein is present in lung cancers could lead to the development of a blood test for the disease (Image: Shutterstock)
While the overall lung cancer five-year survival rate in the U.S. is 15 percent, the odds of survival increase significantly with early detection. However, the expense or invasiveness of current screening methods and the lack of symptoms at early stages of the disease means most people aren’t diagnosed until the cancer is well advanced. Findings by researchers at the University of York could pave the way for a simple blood test that would detect the disease even in its early stages.
Other Images from this Gallery